Results 31 to 40 of about 68,812 (293)

Application of Galectin-3, HBME-1, Cytokeratin-19, and CD56 in the Diagnosis of Thyroid Neoplasm

open access: yesCentral Asian Journal of Medical Sciences, 2019
Objective: The purpose of this study was to investigate the effectiveness of immunohistochemical thyroid malignancy markers Galectin-3, HBME-1, Cytokeratin-19, and CD56 in the diagnosis of thyroid neoplasm. Methods: The study included a total of 53 cases
Suren Okdoo   +7 more
doaj   +1 more source

HETEROGENEITY OF NK AND NKT LYMPHOCYTE POPULATIONS IN HEALTHY DONORS

open access: yesМедицинская иммунология, 2017
Natural killer(NK) and  NKT lymphocytes are important components of innate immunity, and compose a first-line defense against cancer. These populations are characterized by high heterogeneity and are divided into several subpopulations, by differences in
D V. Tabakov   +5 more
doaj   +1 more source

Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma A Cellular Lineage and Clinicopathologic Study of 60 Patients From Asia

open access: yes, 2017
Primary cutaneous, extranodal natural killer/T-cell lymphoma, nasal type (PC-ENKTL), is a rare Epstein-Barr virus (EBV)-associated neoplasm with poorly defined clinicopathologic features.
廖肇裕   +1 more
core   +1 more source

CD56 polysialylation promotes the tumorigenesis and progression via the Hedgehog and Wnt/β-catenin signaling pathways in clear cell renal cell carcinoma

open access: yesCancer Cell International, 2023
Background CD56 has been observed in malignant tumours exhibiting neuronal or neuroendocrine differentiation, such as breast cancer, small-cell lung cancer, and neuroblastoma.
Yuli Jian   +9 more
doaj   +1 more source

Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia.

open access: yesHaematologica, 2000
Large granular lymphocytes derive from two major lineages: one expressing the CD3 surface antigen (T-lymphocytes), and the other lacking this marker (NK-cells). Although developmental overlaps between natural killer cells and T-cells have been described, malignancies derived from these two cell types are considered as distinct lymphoid disorders.We ...
CAMERA, ANDREA   +10 more
openaire   +4 more sources

MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

open access: yesHematology, Transfusion and Cell Therapy, 2022
Objective: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare disease with an aggressive course. Plasmacytoid dendritic cells (PDCs) are a component of the innate immune response: they secrete large amounts of type I interferons ...
Aleksandra Palladina   +3 more
doaj   +1 more source

Phenotypic difference between matured CD56+ and CD56− IL-15 DCs.

open access: yes, 2012
Pairwise comparison of CD56− and CD56+ IL-15 DC surface phenotypes. Results are presented as mean (± SEM) ΔMFI values and as mean (± SEM) percentage of cells staining positive for the indicated cell surface marker. Data are from 7 independent experiments,
Sébastien Anguille (106649)   +8 more
core   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan   +18 more
wiley   +1 more source

Leucemia aguda de células dendríticas linfoplasmocitóides: relato de caso e revisão da literatura. [PDF]

open access: yes, 2006
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Sella, Luiz Fernando
core  

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy